Neurology Central

Immunotherapy in glioblastoma: emerging options in precision medicine


Immunotherapy for glioblastoma (GBM) provides a unique opportunity for targeted therapies for each patient, addressing individual variability in genes, tumor biomarkers and clinical profile. As immunotherapy has the potential to specifically target tumor cells with minimal risk to normal tissue, several immunotherapeutic strategies are currently being evaluated in clinical trials in GBM.

Restricted Content / Members Only

You cannot view this content because It is available to members only. Please or Register to view this area.